Key Takeaways
- Virginia Commonwealth University has signed a letter of intent to acquire Altria Group’s downtown Richmond building for USD 150 million.
- The property covers 450,000 square feet on 4.3 acres and has an assessed value of about USD 275.97 million.
- VCU plans to use the facility to expand the Massey Comprehensive Cancer Center and support its School of Public Health and School of Pharmacy.
- VCU said constructing a similar facility would cost about USD 715 million.
- The acquisition still requires state authorization and funding approval and is under consideration in the state budget process.
2Firsts, March 13, 2026
According to Virginia Business, Virginia Commonwealth University has signed a letter of intent to acquire Altria Group’s 450,000-square-foot building in downtown Richmond for USD 150 million, but whether VCU can move forward with the purchase depends on approval from the General Assembly.
During a February subcommittee meeting of the school’s board of visitors, VCU Chief Financial Officer Meredith Weiss revealed that the university signed the letter of intent to purchase the site at 601 E. Jackson St. According to online tax records, the 4.3-acre property has an assessed value of USD 275.97 million. For more than a year, VCU has been interested in buying the nine-story facility, which includes research labs, a vivarium and academic space.
VCU hopes the purchase would allow it to expand its Massey Comprehensive Cancer Center by adding more research lab space. It also wants to use the facility to grow enrollment in VCU’s new School of Public Health and School of Pharmacy.
Weiss said the site could support research growth across all of the university’s health sciences, in addition to meeting the cancer center’s needs quickly and urgently.
She told the committee that, in her opinion, the property was a once-in-a-lifetime opportunity for VCU and described it as an incredible facility in excellent condition.
She also said constructing a similar facility would cost roughly USD 715 million. At the subcommittee meeting, Weiss recalled that colleagues had informed her the Altria building contained wet labs and office space that could be used for academic initiatives and that the building was likely not being fully utilised. She then contacted and spoke with Altria’s chief financial officer to determine whether there was interest in selling the facility, and there was.
The acquisition is not yet final. VCU spokesperson Michael R. Porter said that while the university is actively seeking to purchase the Altria facility, it still requires authorization and funding approval from the state government.
Porter said in an email that VCU has requested funding from the state to support the acquisition. Because the university needs state funding approval to move forward, he said it is too early to provide details about a closing date, occupancy or renovation costs, although VCU expects the facility will need renovations before it can be occupied.
The matter is being considered in the state budget this year, and budget negotiators are expected to continue working on it until the legislative session adjourns sine die on Saturday.
Porter stressed that VCU needs the facility to support its growing health sciences academic programming and research enterprise.
Altria previously said that if it reached a deal with VCU and the sale closed, it would likely build a new research facility at Philip Morris USA’s Manufacturing Center complex.
An Altria spokesperson declined to comment on the timeline of a potential acquisition or on the company’s plans for the site, saying that approvals are still pending in the General Assembly.
Image source: Virginia Business
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
